title: Exacerbation of infliximab-induced paradoxical psoriasis after ustekinumab therapy.
authors.affiliation: Department of Dermatology, National Medical Center, Seoul, Korea.
authors.forename: Hyun Yi
authors.initials: HY
authors.lastname: Suh
authors.affiliation: Department of Dermatology, National Medical Center, Seoul, Korea.
authors.forename: Ji Young
authors.initials: JY
authors.lastname: Ahn
authors.affiliation: Department of Dermatology, National Medical Center, Seoul, Korea.
authors.forename: Mi Youn
authors.initials: MY
authors.lastname: Park
authors.affiliation: Department of Dermatology, National Medical Center, Seoul, Korea.
authors.forename: Jai Il
authors.initials: JI
authors.lastname: Youn
mesh_terms: D000328:Adult; D003879:Dermatologic Agents / Q000009:adverse effects*; D018450:Disease Progression; D006801:Humans; D000069285:Infliximab / Q000009:adverse effects*; D008297:Male; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology / Q000473:pathology*; D012720:Severity of Illness Index; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000276:immunology; D000069549:Ustekinumab / Q000009:adverse effects*; D028761:Withholding Treatment
chemical_list: D003879:Dermatologic Agents; C439524:TNF protein, human; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000069549:Ustekinumab